3/13/2020: UPDATED ANNOUNCEMENT AVAILABLE HERE » We never want to put anyone from the Duchenne community at risk, and with the statements from the CDC regarding travel risks, especially for persons […]
CureDuchenne congratulates Pfizer on their progress to a Phase III clinical trial for #PF-06939926, its AAV9 mini-dystrophin gene therapy for Duchenne muscular dystrophy. We’re grateful to Pfizer for their dedication […]
The Congressionally Directed Medical Research Programs’ (CDMRP), Duchenne Muscular Dystrophy Research Program (DMDRP) consumer advocates Tiffany Cook and Clint M. Porter recently participated in the evaluation of research applications submitted […]
CureDuchenne, the leading global nonprofit focused on finding a cure for Duchenne muscular dystrophy, will contribute patient-level clinical data to the Vivli platform, making it available to other researchers around […]
Italfarmaco’s EPIDYS clinical trial for Givinostat is enrolling boys age 6 and up at 40 sites around the world. See the details in Italfarmaco’s Winter 2020 community newsletter. Or join […]
In this webinar, Sarepta Therapeutics discusses their patient support program, SareptAssist, intended to support individuals through the process of starting and staying on commercial therapy. Services provided by SareptAssist include […]
Mallinckrodt Comments on its BRAVE study (A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 […]
CureDuchenne has wrapped up our 2019 Webinar Series. We are committed to delivering the most up-to-date and accurate information to the Duchenne Community and are honored to have had the […]
Suvodirsen (formerly known as WVE-210201) is an investigational stereopure oligonucleotide being developed as a potential treatment for boys with Duchenne muscular dystrophy with mutations amenable to exon 51 skipping. Wave […]
